Revive Therapeutics Stock Performance
| RVVTF Stock | USD 0.01 0.0009 15.00% |
Revive Therapeutics has a performance score of 1 on a scale of 0 to 100. The company holds a Beta of 0.0856, which implies not very significant fluctuations relative to the market. As returns on the market increase, Revive Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Revive Therapeutics is expected to be smaller as well. Revive Therapeutics right now holds a risk of 10.95%. Please check Revive Therapeutics treynor ratio, semi variance, as well as the relationship between the Semi Variance and rate of daily change , to decide if Revive Therapeutics will be following its historical price patterns.
Risk-Adjusted Performance
1 of 100
Weak | Strong |
Very Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Revive Therapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, Revive Therapeutics may actually be approaching a critical reversion point that can send shares even higher in January 2025. ...more
| Begin Period Cash Flow | 16.6 M |
Revive |
Revive Therapeutics Relative Risk vs. Return Landscape
If you would invest 0.90 in Revive Therapeutics on September 13, 2024 and sell it today you would lose (0.21) from holding Revive Therapeutics or give up 23.33% of portfolio value over 90 days. Revive Therapeutics is currently producing 0.1742% returns and takes up 10.9463% volatility of returns over 90 trading days. Put another way, 97% of traded otc stocks are less volatile than Revive, and 97% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Revive Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Revive Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Revive Therapeutics, and traders can use it to determine the average amount a Revive Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0159
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | RVVTF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 10.95 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.17 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average Revive Therapeutics is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Revive Therapeutics by adding it to a well-diversified portfolio.
Revive Therapeutics Fundamentals Growth
Revive OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Revive Therapeutics, and Revive Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Revive OTC Stock performance.
| Return On Equity | -0.83 | |||
| Return On Asset | -0.43 | |||
| Current Valuation | 32.12 M | |||
| Shares Outstanding | 353.56 M | |||
| Price To Earning | (4.10) X | |||
| Price To Book | 4.00 X | |||
| EBITDA | (17.74 M) | |||
| Cash And Equivalents | 5.29 M | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 60 K | |||
| Debt To Equity | 0.02 % | |||
| Book Value Per Share | 0.03 X | |||
| Cash Flow From Operations | (13.06 M) | |||
| Earnings Per Share | (0.06) X | |||
| Total Asset | 17.07 M | |||
| Retained Earnings | (4.38 M) | |||
| Current Asset | 635 K | |||
| Current Liabilities | 503 K | |||
About Revive Therapeutics Performance
By analyzing Revive Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Revive Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Revive Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Revive Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company was incorporated in 2012 and is headquartered in Toronto, Canada. Revive Therapeutics is traded on OTC Exchange in the United States.Things to note about Revive Therapeutics performance evaluation
Checking the ongoing alerts about Revive Therapeutics for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Revive Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Revive Therapeutics had very high historical volatility over the last 90 days | |
| Revive Therapeutics has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (17.81 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Revive Therapeutics has accumulated about 5.29 M in cash with (13.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Revive Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Revive Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Revive Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Revive Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Revive Therapeutics' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Revive Therapeutics' otc stock. These opinions can provide insight into Revive Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Revive OTC Stock analysis
When running Revive Therapeutics' price analysis, check to measure Revive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Revive Therapeutics is operating at the current time. Most of Revive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Revive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Revive Therapeutics' price. Additionally, you may evaluate how the addition of Revive Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |